Notwithstanding positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial difficulty from pharmacy benefit managers. These organizations are frequently erecting barriers to coverage, like high expense criteria and appr